Company: LGNZZ
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0000886163-25-000051
Chunk: 10

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-08-08
Form: 10-Q
Item: Item 1
Chunk 10
---
 or measure performance of segments using asset information.The information on significant segment expenses that are regularly provided to the CODM, and other segment items included within the reported segment profit or loss measure, is presented in a table below:Three months endedSix months ended June 30,June 30,2025202420252024Total revenues and other income$47,627 $41,531 $92,960 $72,509 Share-based compensation(9,997)(11,060)(17,833)(18,394)Other segment items:Amortization of intangibles(8,258)(8,257)(16,515)(16,443)Depreciation of property and equipment(264)(596)(777)(1,175)Interest income1,621 2,757 3,392 4,777 Interest expense(1,153)(1,268)(2,020)(1,411)Other *(24,729)(75,018)(96,811)(5,635)Net income (loss)$4,847 $(51,911)$(37,604)$34,228 * Other items for the three months ended June 30, 2025 include the amount of other general, administrative, research and development expenses of $16.5 million (net of share-based compensation and depreciation expenses), and additional income and expense items that are presented in the unaudited condensed statements of operations such as fair value adjustments to partner program derivatives, cost of Captisol and other non-operating income and expenses. Other items for the six months ended June 30, 2025 include the amount of other general, administrative, research and development expenses of $77.0 million (including a $44.3 million one-time research and development expense in connection with the Castle Creek Transaction, and net of share-based compensation and depreciation expenses ), and additional income and expense items that are presented in the unaudited condensed statements of operations such as fair value adjustments to partner program derivatives, cost of Captisol and other non-operating income and expenses.Other items for the three months ended June 30, 2024 include the amount of other general, administrative, research and development expenses of $11.3 million (net of share-based compensation and depreciation expenses), and additional operating income and expense items that are presented in the unaudited condensed statements of operations such as financial royalty assets impairment of $26.5 million, cost of Captisol and other non-operating income and expenses (including